PDIA3 and breast carcinoma: With regard to clinical outcomes, PDIA3 expression was searched against the breast cancer data sets in the GOBO database (42) and found to correlate with significantly reduced (P value <0.05) distant metastasis-free survival (DMFS) over 10 yr for all tumors; basal subtype tumors; estrogen receptor (ER)-positive tumors; lymph node-negative tumors, and ER-positive, lymph node-negative tumors (Fig. 7B).